What is Acrivon Therapeutics?
Acrivon Therapeutics is a precision oncology company that distinguishes itself through a proprietary proteomics-based patient selection platform. Unlike traditional drug development models that rely on simple genetic markers, Acrivon utilizes a sophisticated methodology applicable across diverse drug classes and modalities. This approach is specifically designed to tackle challenging oncology targets that are causally implicated in the majority of cancer cases, particularly those that have historically proven difficult to treat due to the absence of synthetic lethal contexts.
Headquartered in the greater Boston area, with dedicated biomarker discovery operations in Lund, Sweden, the company maintains a robust clinical biomarker development group. This dual-geography structure allows Acrivon to integrate cutting-edge discovery with rigorous clinical execution, ensuring that its pipeline of in-licensed and internally developed assets is supported by high-fidelity patient selection data.
How much funding has Acrivon Therapeutics raised?
Acrivon Therapeutics has raised a total of $100M across 1 funding round:
Series B
$100M
Series B (2022): $100M with participation from Wellington Management, RA Capital Management, Surveyor Capital, and Perceptive Advisors
Key Investors in Acrivon Therapeutics
Wellington Management
Wellington Management is a global, independent investment firm that provides institutional clients with tailored portfolio management and research solutions across diverse asset classes.
RA Capital Management
RA Capital Management is a multi-stage investment manager specializing in evidence-based investing within the healthcare and life sciences sectors, supported by its internal TechAtlas research group.
Surveyor Capital
Surveyor Capital is a specialized equity business under the Citadel umbrella, functioning as a platform for long/short equity hedge fund managers.
What's next for Acrivon Therapeutics?
Looking ahead, the recent capital injection will be instrumental in scaling Acrivon Therapeutics' clinical operations. The company is expected to prioritize the advancement of its lead assets through accelerated registration trials, a move that could significantly shorten the time-to-market for its therapeutic candidates. Furthermore, the firm will likely continue to refine its proteomics platform, expanding its utility to address a broader spectrum of oncology indications.
As the company matures, the focus will shift toward demonstrating the clinical efficacy of its biomarker-driven strategy in human trials. By maintaining a disciplined approach to research and development, Acrivon aims to establish a new standard in precision oncology, potentially transforming the treatment landscape for patients with limited therapeutic options. The strategic support from its institutional backers provides the stability required to navigate the complexities of late-stage clinical development and regulatory approval processes.
